Tempus AI Inc. (NASDAQ:TEM), a healthcare-focused artificial intelligence company, specializes in developing AI-driven tools to enhance medical diagnostics and treatment options. The company is set to release its quarterly earnings on Tuesday, February 24, 2026, after market close. Wall Street estimates an earnings per share (EPS) of approximately -$0.04, with projected revenue around $362.6 million.
Despite a negative price-to-earnings (P/E) ratio of -49.16, Tempus AI's stock price recently rose. This increase followed Mizuho's initiation of coverage with an Outperform rating, as highlighted by analyst Bradley Bowers, who set a price target of $100. This suggests optimism about the company's future prospects despite current negative earnings.
Tempus AI's recent announcement of a new HRD-RNA algorithm is noteworthy. This AI-driven tool aims to improve the detection of homologous recombination deficiency in tumors. In a real-world validation study, patients with HRD-RNA-positive metastatic pancreatic cancer treated with first-line platinum-based regimens showed a significant reduction in mortality risk. This development could enhance the company's market position.
Financially, Tempus AI has a price-to-sales ratio of about 8.96, indicating that investors are willing to pay nearly nine times the company's sales. The enterprise value to sales ratio is approximately 9.58, reflecting the company's valuation relative to its sales. However, the enterprise value to operating cash flow ratio is around -47.99, indicating negative cash flow.
The company's debt-to-equity ratio is about 2.63, suggesting it has more than twice as much debt as equity. Despite this, Tempus AI maintains a strong current ratio of approximately 3.28, indicating a solid ability to cover short-term liabilities with short-term assets. This financial stability may reassure investors as the company continues to innovate in the healthcare AI sector.
